Thursday, October 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· March 5, 2026

Funding Circle Full Year 2025 Results, Achieves FY 2026 Revenue Guidance a Year Early

View original at globenewswire.com
Funding Circle Full Year 2025 Results, Achieves FY 2026 Revenue Guidance a Year Early LONDON, March 05, 2026 (GLOBE NEWSWIRE) -- Funding Circle Holdings plc (“Funding Circle” or the “Group”) today announces results for the twelve months ended 31 December 2025…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • 50% of Card customers are new to Funding Circle and the new shorter-term lending product has unlocked previously untapped segments of the SME market

    80% confidence
  • Annualised net returns to institutional investors continued to be approximately 5% above cost of capital, resulting in continued investor demand with £2.2bn in committed forward flows

    80% confidence
  • Funding Circle delivered a standout performance in 2025, exceeding expectations and hitting 2026 revenue guidance a year early, supporting more SMEs than ever before

    80% confidence
  • In 2025, lending through Funding Circle supported over 117,000 jobs and contributed £7.9bn to UK GDP. Every £1 million of lending contributed £2.7 million to GDP, 39 jobs and £700,000 in tax revenue

    80% confidence
  • Nearly 70% of FlexiPay revenue comes from existing Term Loan customers, as the company deepens engagement and captures a larger share of customers' financing needs

    80% confidence
  • 15 years of proprietary data and technology expertise are the foundation of Funding Circle's competitive advantage, allowing delivery of superior customer experience

    80% confidence
  • Strong growth in credit extended led to revenue growth of 28% to £204m and profit before tax increasing to £20m, demonstrating strong operating leverage and profitability

    80% confidence
  • There is a significant opportunity to further grow share of the SME finance market, with confidence in the strength and scalability of the platform reflected in new medium-term targets

    80% confidence
  • AI-powered credit models are 3x better at discriminating risk than traditional bureau scores, with 15 years of proprietary data including 10 billion data points feeding model development

    80% confidence
  • Funding Circle interacts with a customer once every 38 seconds, positioning the company at the heart of their businesses as a trusted financial partner

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com